Labcorp Enhances Cell and Gene Therapy Development Support Through Collaboration with Xcell Biosciences

Ovia Health Taps Digital Health Innovator Dr. Leslie Saltzman as Chief Medical Officer

Needs Beyond Medicine Receives $10,000 Grant from the Labcorp Charitable Foundation

April 7, 2022

Labcorp initiates quarterly dividend

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 7, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock. 
April 5, 2022

New Immundiagnostik test simplifies detecting, measuring unintentional gluten consumption

MANCHESTER, N.H., April 5, 2022 — Immundiagnostik, Inc., the North American subsidiary of Immundiagnostik AG, has collaborated with Labcorp (NYSE: LH), a leading global life sciences company, to help individuals detect and quantify unintentional gluten consumption by utilizing a new fecal gluten test. The quantitative test developed by Immundiagnostik and offered exclusively through Labcorp detects the presence of gluten in a patient’s stool sample and has a high sensitivity and specificity.

New Immundiagnostik Test Simplifies Detecting, Measuring Unintentional Gluten Consumption

Labcorp Renews Strategic Partnership with Medidata to Provide Suite of Clinical Trial Technologies and Services